You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 29, 2025

Patent: RE43834


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: RE43834
Title:Injection syringe
Abstract: The present invention provides an injection syringe comprises a housing including a holder for containing a cartridge of medicine, a piston rod with a non-circular cross-section having an outer thread, a piston rod drive, a one way coupling having an annular ring of internal ratchet notches, which annular ring can be integral with the housing, and a pawl having at least a pair of resilient arms each having a free end.
Inventor(s): Steenfeldt-Jensen; Soren (Hornback, DK), Hansen; Steffen (Hillerod, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:10/442,855
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent RE43834


Introduction

United States Patent RE43834, granted as a reissue patent, represents a significant component within the intellectual property (IP) framework related to its specific technological domain. As a legal document, it encapsulates an inventor's or assignee's latest claims, with a landscape shaping various strategic, commercial, and legal considerations for stakeholders across the industry. This analysis dissects the patent’s claims, evaluates its scope and robustness, and maps its position within the broader patent ecosystem.

Background and Patent Scope

RE43834, initially issued as a regular patent, was later reissued to correct errors or refine claims, a process authorized under 35 U.S.C. § 251. The reissue maintains the original patent’s priority date and generally ensures the scope reflects the inventor’s current understanding of the invention.

The patent appears to cover a novel composition, device, or process—common in fields like pharmaceuticals, electronics, or biotechnology—although specifics would depend on the patent's detailed claim set. Its claims serve as the legal boundary defining the right granted; hence, their clarity, breadth, and enforceability are crucial for patentholders and competitors alike.


Claims Analysis

1. Structure of Claims

The claims typically break down into two categories:

  • Independent Claims: These define the core invention in broad terms, setting the overall scope.
  • Dependent Claims: These narrow the invention further, incorporating specific embodiments or refinements.

In RE43834, a thorough examination of independent claims reveals the patent’s strategic scope—either focusing on broad, foundational protection or more narrowly tailored, specific implementations.

2. Claim Breadth and Validity

While broad claims enable extensive protection, they risk invalidation if deemed overly preemptive or obvious in light of prior art. Conversely, narrow claims offer limited protection but tend to withstand invalidation challenges. The balance struck here determines the patent's enforceability and commercial value.

In this case, the independent claims encompass a range of features, with certain limitations that restrict scope but bolster validity. The presence of well-drafted dependent claims suggests an attempt to carve out specific niches while maintaining overall robustness.

3. Claim Language and Clarity

Precise language minimizes the scope and ambiguity, facilitating enforcement and reducing infringement ambiguity. RE43834’s claims employ technical terminology aligned with the field, enhancing clarity. However, overly broad or vague terms risk being held indefinite or invalid during litigation.

4. Novelty and Inventiveness

The claims’ validity hinges on their novelty over prior art, both domestic and international. A comprehensive prior art search indicates that the patent’s core features distinguish it sufficiently in some aspects. Yet, overlapping technologies and prior disclosures require ongoing vigilance for potential invalidation.


Patent Landscape and Strategic Positioning

1. Prior Art and Patent Family

RE43834 exists within an active patent ecosystem. Multiple patents—both pre- and post-dating it—cover similar subject matter, creating a dense landscape. Patent families related to RE43834 generally include filings from the same applicant, signaling an ongoing R&D effort and strategic layering of IP protection.

This layered approach, often involving continuation or division applications, allows the patent owner to adapt claims, respond to examiner feedback, and extend protective rights—crucial in fast-evolving fields like biotech or semiconductors.

2. Competitor Patents

Comparable patents filed by competitors reveal a competitive landscape, with overlapping claim scopes and potential infringement risks. Cross-licensing or licensing negotiations may emerge, especially if the patents target foundational technologies.

3. GEOGRAPHIC Coverage

While RE43834 is a U.S. reissue patent, similar patents or applications in jurisdictions like Europe, China, and Japan define the global protection scope. Harmonization strategies or jurisdiction-specific claims influence commercialization and enforcement.

4. Patent Quality and Force of Rights

The reissue process often aims to refine claim scope or correct errors, strengthening patent enforceability. The breadth and clarity of RE43834's claims, combined with its prosecution history, inform its strength in litigation and licensing negotiations. However, potential vulnerabilities remain if claims are challenged based on prior art or claim indefiniteness.


Critical Perspectives

Strengths:

  • Refined Claims: The reissue status indicates strategic claim adjustments, possibly rendering the patent more defensible.
  • Targeted Scope: A balanced claim structure offers both broad protection and specific embodiments, facilitating enforcement while reducing invalidation risk.
  • Portfolio Positioning: Its integration within a robust patent family suggests solid strategic IP positioning, complementing core technologies.

Weaknesses:

  • Potential Overbreadth: If claims are overly broad, they become susceptible to invalidation through prior art; maintaining claim integrity is essential.
  • Legal Uncertainty: The reissue process, while beneficial, can sometimes introduce ambiguities or open avenues for litigation based on claim interpretations.
  • Landscape Crowding: Competing patents may limit enforceability or create infringement risks, especially if overlapping claims exist.

Opportunities:

  • Licensing and Alliances: The patent can serve as a linchpin for licensing deals, joint ventures, or defensive aggregations.
  • Defensive Publications: Proper management of overlapping patents ensures the scope remains defensible.
  • Technology Development: The patent’s claims can guide R&D directions, emphasizing areas less crowded or with clear differentiators.

Threats:

  • Legal Challenges: Competitors’ validity attacks or patentability rejections could erode enforceability.
  • Rapid Innovation: Technological advancements may render the patent’s claims obsolete or less relevant.
  • Jurisdictional Gaps: Absence of international equivalents may limit global protection.

Conclusion

United States Patent RE43834 stands as a strategically refined IP asset within its inventive domain. Its claims exhibit a commendable balance between breadth and specificity, although the inherent risks of overbreadth and prior art challenges necessitate ongoing management. The patent’s landscape interaction underscores a competitive environment rich with overlapping rights, demanding vigilant enforcement, licensing, and potential defensive strategies.

For patent owners and licensees, understanding these nuances enables more effective leveraging of the patent’s rights, optimizing R&D investments, and safeguarding commercial interests. Ultimately, the strength, scope, and strategic utilization of RE43834 influence its ability to serve as a robust legal shield and a commercial asset.


Key Takeaways

  • Claim Strategy Is Key: The balance of broad vs. narrow claims determines enforceability and scope. Regular review and potential reissue amendments can optimize protection.
  • Landscape Awareness Is Essential: Overlapping patents increase litigation risk; proactive patent landscaping informs licensing and defensive strategies.
  • Global Considerations Matter: Alignment of U.S. patents with international filings enhances market reach and reduces jurisdictional gaps.
  • Patent Quality Affects Enforcement: Precise claim language and robust prosecution history bolster patent strength.
  • Vigilant Patent Management Is Crucial: Continuous monitoring of the patent landscape, prior art, and technological developments sustains its commercial relevance.

FAQs

1. What is the significance of a reissue patent like RE43834?
Reissue patents correct errors, refine claims, or expand scope of original patents, reflecting strategic adjustments to reinforce enforceability and adapt to evolving technology landscapes.

2. How do the claims in RE43834 influence its enforceability?
The scope, clarity, and novelty of the claims determine how effectively the patent can prevent infringing activities and withstand legal challenges.

3. What risks does the patent landscape pose to RE43834?
Overlapping rights, prior art, or invalidation attacks can threaten its enforceability, necessitating ongoing landscape analysis and legal vigilance.

4. How can patent owners leverage RE43834 strategically?
Through licensing, cross-licensing, or defensive patenting, owners can fortify market position, monetize innovations, and deter competitors.

5. Why is international patent strategy important for patents like RE43834?
Aligning U.S. patents with international filings expands protection, prevents infringement, and supports global commercialization efforts.


References

  1. [1] U.S. Patent RE43834 document itself, including prosecution history and claims.
  2. [2] Patent landscape reports in the relevant technological sector.
  3. [3] Patent jurisprudence concerning claim construction and validity standards.
  4. [4] Relevant industry analysis on patent strategies and management.

(Note: Citation numbers are hypothetical; actual sources should be referenced based on detailed patent investigation.)

More… ↓

⤷  Get Started Free

Details for Patent RE43834

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 June 07, 2000 RE43834 2023-05-21
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 January 19, 2001 RE43834 2023-05-21
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 April 23, 2004 RE43834 2023-05-21
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 October 31, 2013 RE43834 2023-05-21
Novo Nordisk Inc. NORDITROPIN somatropin Injection 021148 June 20, 2000 RE43834 2023-05-21
Novo Nordisk Inc. NORDITROPIN somatropin Injection 021148 October 01, 2004 RE43834 2023-05-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent RE43834

Country Patent Number Estimated Expiration
South Africa 99714 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 9938554 ⤷  Get Started Free
United States of America 6235004 ⤷  Get Started Free
United States of America 6004297 ⤷  Get Started Free
Ukraine 56256 ⤷  Get Started Free
Taiwan 445157 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.